BRPI0920521A2 - combinação farmacêutica - Google Patents

combinação farmacêutica

Info

Publication number
BRPI0920521A2
BRPI0920521A2 BRPI0920521A BRPI0920521A BRPI0920521A2 BR PI0920521 A2 BRPI0920521 A2 BR PI0920521A2 BR PI0920521 A BRPI0920521 A BR PI0920521A BR PI0920521 A BRPI0920521 A BR PI0920521A BR PI0920521 A2 BRPI0920521 A2 BR PI0920521A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical combination
pharmaceutical
combination
Prior art date
Application number
BRPI0920521A
Other languages
English (en)
Portuguese (pt)
Inventor
Schiene Klaus
Bloms-Funke Petra
Christoph Thomas
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40345058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0920521(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of BRPI0920521A2 publication Critical patent/BRPI0920521A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0920521A 2008-09-05 2009-09-04 combinação farmacêutica BRPI0920521A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05
PCT/EP2009/006424 WO2010025931A2 (en) 2008-09-05 2009-09-04 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
BRPI0920521A2 true BRPI0920521A2 (pt) 2018-01-16

Family

ID=40345058

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920521A BRPI0920521A2 (pt) 2008-09-05 2009-09-04 combinação farmacêutica

Country Status (28)

Country Link
US (1) US20100063148A1 (enExample)
EP (2) EP2735338B1 (enExample)
JP (4) JP5731387B2 (enExample)
KR (3) KR101730924B1 (enExample)
CN (2) CN102159284B (enExample)
AR (2) AR073361A1 (enExample)
AU (3) AU2009289776A1 (enExample)
BR (1) BRPI0920521A2 (enExample)
CA (1) CA2735857C (enExample)
CL (1) CL2011000317A1 (enExample)
CO (1) CO6382142A2 (enExample)
CY (2) CY1115751T1 (enExample)
DK (2) DK2735338T3 (enExample)
EC (1) ECSP11010869A (enExample)
ES (2) ES2719900T3 (enExample)
HR (2) HRP20140663T1 (enExample)
HU (1) HUE043278T2 (enExample)
IL (3) IL211135A (enExample)
LT (1) LT2735338T (enExample)
MX (1) MX2011002339A (enExample)
PE (5) PE20142357A1 (enExample)
PL (2) PL2735338T3 (enExample)
PT (2) PT2735338T (enExample)
RU (2) RU2674150C1 (enExample)
SI (2) SI2735338T1 (enExample)
TR (1) TR201904388T4 (enExample)
WO (1) WO2010025931A2 (enExample)
ZA (1) ZA201101449B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
JP5443981B2 (ja) * 2006-06-15 2014-03-19 ウーツェーベー ファルマ ゲーエムベーハー 相乗的抗痙攣効果を有する医薬組成物
PE20142357A1 (es) * 2008-09-05 2015-02-04 Gruenenthal Chemie Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
CN103108631B (zh) * 2010-06-15 2015-08-26 格吕伦塔尔有限公司 用于治疗疼痛的联合药物
WO2012003968A1 (en) 2010-07-06 2012-01-12 Grünenthal GmbH Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
EP2599487B1 (en) 2010-07-30 2015-04-01 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
CN107088226A (zh) * 2011-03-04 2017-08-25 格吕伦塔尔有限公司 他喷他多的胃肠外给药
US11413239B2 (en) * 2011-07-20 2022-08-16 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol for nasal administration
EP2736501B1 (en) * 2011-07-29 2017-12-20 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9320725B2 (en) * 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
CA2890270A1 (en) * 2012-11-01 2014-05-08 Torrent Pharmaceuticals Ltd Pharmaceutical composition of tapentadol for parenteral administration
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
MX391077B (es) 2015-12-22 2025-03-21 Zogenix International Ltd Composiciones de fenfluramina y métodos de preparación de las mismas.
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
EP4201427A1 (en) 2016-08-24 2023-06-28 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
WO2001013904A2 (en) * 1999-08-20 2001-03-01 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
KR20040085216A (ko) * 2002-02-22 2004-10-07 워너-램버트 캄파니 엘엘씨 알파-２-델타 리간드와 시클로옥시게나제-２의 선택적인억제제의 조합 제제
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
AU2007247480B8 (en) * 2006-04-28 2013-04-11 Grunenthal Gmbh Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
CN104958282B (zh) * 2007-11-23 2018-05-29 格吕伦塔尔有限公司 他喷他多组合物
CA2706575C (en) * 2008-01-25 2015-07-14 Xenoport, Inc. Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
PE20142357A1 (es) * 2008-09-05 2015-02-04 Gruenenthal Chemie Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico

Also Published As

Publication number Publication date
ECSP11010869A (es) 2011-04-29
PL2735338T3 (pl) 2019-07-31
IL237392B (en) 2019-08-29
EP2331210B1 (en) 2014-07-09
KR101641519B1 (ko) 2016-07-21
KR20160086981A (ko) 2016-07-20
PT2735338T (pt) 2019-05-24
PE20142357A1 (es) 2015-02-04
SI2735338T1 (sl) 2019-04-30
JP2019131578A (ja) 2019-08-08
US20100063148A1 (en) 2010-03-11
CN105520924A (zh) 2016-04-27
KR101851120B1 (ko) 2018-04-23
LT2735338T (lt) 2019-04-10
KR20170048602A (ko) 2017-05-08
CN105520924B (zh) 2019-04-09
IL237391A (en) 2017-12-31
EP2735338B1 (en) 2019-02-06
CY1115751T1 (el) 2017-01-25
RU2011112444A (ru) 2012-10-10
PE20190914A1 (es) 2019-06-26
CN102159284B (zh) 2015-12-09
HK1198145A1 (en) 2015-03-13
WO2010025931A3 (en) 2010-06-17
CA2735857C (en) 2019-05-28
CO6382142A2 (es) 2012-02-15
ZA201101449B (en) 2011-10-26
JP5731387B2 (ja) 2015-06-10
CA2735857A1 (en) 2010-03-11
AU2018202879A1 (en) 2018-05-17
PE20142372A1 (es) 2015-02-04
EP2331210A2 (en) 2011-06-15
IL237391A0 (en) 2015-04-30
CL2011000317A1 (es) 2011-06-17
MX2011002339A (es) 2011-04-04
ES2719900T3 (es) 2019-07-16
HUE043278T2 (hu) 2019-08-28
AR073361A1 (es) 2010-11-03
DK2331210T3 (da) 2014-08-11
HK1159011A1 (en) 2012-07-27
IL237392A0 (en) 2015-04-30
CY1121492T1 (el) 2020-05-29
AU2018202879B2 (en) 2020-03-12
JP2012501986A (ja) 2012-01-26
AU2009289776A1 (en) 2010-03-11
PE20142371A1 (es) 2015-02-04
PT2331210E (pt) 2014-08-25
HRP20140663T1 (hr) 2014-10-10
HRP20190500T1 (hr) 2019-08-09
AR117613A2 (es) 2021-08-18
KR20110057144A (ko) 2011-05-31
TR201904388T4 (tr) 2019-05-21
ES2513394T3 (es) 2014-10-27
RU2674150C1 (ru) 2018-12-05
IL211135A (en) 2017-09-28
EP2735338A1 (en) 2014-05-28
PE20110291A1 (es) 2011-06-04
JP2017071636A (ja) 2017-04-13
IL211135A0 (en) 2011-04-28
PL2331210T3 (pl) 2014-12-31
DK2735338T3 (en) 2019-04-23
AU2016203053A1 (en) 2016-06-02
SI2331210T1 (sl) 2014-10-30
CN102159284A (zh) 2011-08-17
WO2010025931A2 (en) 2010-03-11
RU2571501C2 (ru) 2015-12-20
KR101730924B1 (ko) 2017-04-27
AU2016203053B2 (en) 2018-01-25
JP2015096530A (ja) 2015-05-21

Similar Documents

Publication Publication Date Title
BRPI0920521A2 (pt) combinação farmacêutica
DK2370462T3 (da) Glucagon-analoger
DK2342317T3 (da) Hængende-dråbe-plade
DE602009000234D1 (de) msignals
BRPI0907376A2 (pt) Fotobiorretador
DK3444343T3 (da) Polypeptider
BRPI0914649A2 (pt) Piprazolo-quinazolinas
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DK2342454T3 (da) Vindkraftanlæg
DK2335031T3 (da) In-line-måler
DK2336132T3 (da) Morpholinpurinderivat
DK2285413T3 (da) Farmaceutisk sammensætning
DK2379557T3 (da) Aminopyrazol-forbindelse
EP2236149A4 (en) MEDICAL COMPOSITION
BRPI0921654A2 (pt) formulação farmacêutica
DK2271613T3 (da) Hydroxymethylcyklohexylaminer
DE602008003970D1 (de) Strahlstromkalibriersystem
BRPI0921313A2 (pt) composição farmaucêutica
BRPI0907522A2 (pt) biarlamidas
DE112009000183A5 (de) Sicherheitsvorreiber
DK2271618T3 (da) Farmaceutiske forbindelser
DK2272763T3 (da) Blisterpakning-dispensermaskine
BRPI0909634A2 (pt) 2-aminoquinolinas
DE602009000862D1 (de) Gehwagenbremse

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.